15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Monopar Therapeutics Inc, 11 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $74.00 to $125.00, a moderate spread. The average target of $108.18 sits 2% below the current $110.45. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.77 next quarter toward $-3.13 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Moderate Buy
Strong Buy00%
Buy11100%
Hold00%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Monopar Therapeutics Inc.
As of Jul, 11 of 11 firms rate MNPR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MNPR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.77
Range $-1.38 – $-0.32 · 11 analysts · +60% YoY
Next period, 11 analysts expect Monopar Therapeutics Inc to earn $-0.77 a share (range $-1.38 – $-0.32), versus $-0.48 a year earlier. Full-year consensus is $-2.90, growing to $-3.13 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 11 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $15.8M next year.
Top analysts covering Monopar Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MNPR.
#1
Keay Nakae
Chardan Capital · Rank #130
Buy
$100.00-9.5% to target
Overall win rate
41%
+ Follow
#2
Kristen Kluska
Cantor Fitzgerald · Rank #162
Buy
$109.00-1.3% to target
Overall win rate
38%
+ Follow
#3
Sean Lee
HC Wainwright & Co. · Rank #191
Buy
$40.00-63.8% to target
Overall win rate
43%
+ Follow
#4
Andres Y. Maldonado
HC Wainwright & Co. · Rank #211
Buy
$105.00-4.9% to target
Overall win rate
38%
+ Follow
#5
JM
Jeet Mukherjee
BTIG
Buy
$117.00+5.9% to target
Coverage
—
+ Follow
MNPR stock forecast FAQ
What is MNPR's average 12-month price target?+
The 11 analysts with a live target average $108.18 for Monopar Therapeutics Inc over the next 12 months, ranging from a $125.00 high to a $74.00 low.
Is MNPR stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 11 analyst ratings, 11 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MNPR?+
The Street-high target is $125.00 (Barclays), and the Street-low is $74.00 (Cantor Fitzgerald). The average of all 11 active targets is $108.18.
How many Wall Street analysts cover MNPR?+
11 analysts have an active rating on Monopar Therapeutics Inc, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering MNPR?+
Among analysts who currently cover MNPR, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Buy with a $100.00 target.
What is Monopar Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.77 per share (range $-1.38 – $-0.32) across 11 analysts. Full-year EPS is projected at $-2.90, rising to $-3.13 the following year.
How much revenue is Monopar Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $15.8M next year.
Have analysts been upgrading or downgrading MNPR lately?+
As of Jul, 11 of 11 firms rate MNPR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MNPR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
